Drug updated on 12/11/2024
| Dosage Form | Injection (subcutaneous; 0.3 mg/mL, 0.6 mg/mL, 0.9 mg/mL) |
| Drug Class | Somatostatin analogs |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option
- Indicated for the treatment of patients with Cushings disease for whom pituitary surgery is not an option or has not been curative.
Latest News
Summary
- This summary is based on the review of one randomized controlled trial. [1]
- Pasireotide significantly reduced urinary-free cortisol (UFC) levels in patients with Cushing's disease (CD).
- Tumor volume reduction was dose- and time-dependent, with 75% of patients in the 900-µg group experiencing tumor reduction at month 6 versus 44% in the 600-µg group. By month 12, 89% of patients in the 900-µg group showed tumor reduction compared to 50% in the 600-µg group. Control of UFC levels was not a requirement for tumor volume reduction.
- There is no safety information available in the reviewed studies.
- There is no population types or subgroups information available in the reviewed studies.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Signifor (pasireotide) Prescribing Information. | 2024 | Recordati Rare Diseases Inc., Bridgewater, NJ |
Randomized Controlled Trials
| Document Title | Sex Distribution | Year | Source |
|---|---|---|---|
| Pasireotide treatment significantly reduces tumor volume in patients with Cushing's disease: results from a Phase 3 study | 162Subjects F: 78% M: 22% | 2020 | Pituitary |
Document Title
Sex Distribution:
F:78%
M:22%
162Subjects
Year:
2020
Source:Pituitary